Welcome to our dedicated page for Sensei Biotherapeutics SEC filings (Ticker: SNSE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sensei Biotherapeutics, Inc. filings document a Nasdaq-listed clinical-stage oncology company, its common stock, and its disclosure obligations around pipeline development, operating results, governance, and capital structure. Material-event reports cover financial results, Regulation FD disclosures, board composition and compensation arrangements, and the completed acquisition of Faeth Therapeutics, including acquired-business financial statements and pro forma combined financial information.
Proxy and governance filings describe shareholder voting matters, director and board matters, equity compensation, preferred stock conversion-related disclosures, authorized-share matters, material agreements, and other capital-structure topics. The filing record also reflects clinical and regulatory disclosure categories for PIKTOR and solnerstotug within the company’s oncology development business.
Faeth Therapeutics, Inc. Chief Financial Officer Brian C. Stephenson, through the Brian Stephenson Revocable Trust, reported open-market purchases of a total of 13,634 shares of common stock over three days. On June 29 and 30, 2026, and July 1, 2026, the trust bought multiple blocks of shares at weighted average prices disclosed in the filing, including 4,400 shares at $23.40 and 4,255 shares at $24.98. Following the latest transaction, the trust holds 46,688 shares of Faeth Therapeutics common stock. The footnotes state that Stephenson is the sole trustee of the revocable trust, with sole voting and investment power, while disclaiming beneficial ownership beyond his pecuniary interest.
Faeth Therapeutics, Inc.’s Chief Financial Officer Brian C. Stephenson reported multiple indirect open-market purchases of the company’s common stock. Over June 24 and June 26, 2026, a revocable trust associated with him bought a total of 15,641 shares at prices ranging from about $23.61 to $27.77 per share. Following these transactions, the trust held 33,054 shares of Faeth Therapeutics common stock. The shares are held by the Brian Stephenson Revocable Trust, where he is sole trustee with sole voting and investment power, while he disclaims beneficial ownership except to the extent of his pecuniary interest.
Faeth Therapeutics, Inc. Chief Financial Officer Brian C. Stephenson, through the Brian Stephenson Revocable Trust, reported a series of open-market purchases of the company’s common stock. Over June 22–23, 2026, the trust bought a total of 17,413 shares in eight separate transactions.
The reported weighted average purchase prices ranged from about $19.5765 to $26.31 per share across those trades. All holdings reported in this filing are indirect, held by the revocable trust for which Stephenson serves as sole trustee with sole voting and investment power, and amount to 17,413 shares after these transactions.
Faeth Therapeutics, Inc. President and CEO Anand Kiran Parikh increased his direct stake through option exercises and an open-market stock purchase. He exercised employee stock options to acquire 53,465 shares of common stock at $1.16 per share and bought an additional 2,806 shares in the open market at $19.76 per share, all on June 22, 2026. Following these transactions, he directly owns 764,234 shares of Faeth Therapeutics common stock.
Faeth Therapeutics, Inc. filed an initial ownership report for its Chief Financial Officer, Brian C. Stephenson, showing a stock option to purchase common stock. The option covers 166,435 underlying shares at an exercise price of $29.37 per share and expires on March 10, 2036.
According to the vesting terms, 25% of the shares subject to the option vest and become exercisable on March 11, 2027. The remaining shares vest in 36 equal monthly installments thereafter, so the option is fully vested by March 11, 2030, subject to his continuous service with the company.
Faeth Therapeutics, Inc. shareholders Suvretta Capital Management, LLC, Averill Master Fund, Ltd. and Aaron Cowen reported beneficial ownership stakes in the company via a joint Schedule 13G filing. The filing lists 2,020,103 shares (7.8%) for Suvretta and Mr. Cowen and 1,722,652 shares (6.7%) for Averill, based on 25,778,754 shares outstanding as of June 15, 2026. The filing states these securities are directly owned by advisory clients of Suvretta Capital, that Mr. Cowen is the control person and managing member of Suvretta, and that a joint filing agreement and control-person identification exhibit are attached.
Faeth Therapeutics: S2G Investments, LLC reports beneficial ownership of 2,575,401 shares of common stock, equal to 9.99% of the class as of June 15, 2026. The filing states these shares reflect conversion on June 15, 2026 of Series B Non‑Voting Convertible Preferred Stock, each convertible into 1,000 common shares, and that 25,778,754 shares outstanding is the denominator used for the percentage. The filer also holds 344.271 shares of Series B Preferred (approximately 344,271 common shares on an as‑converted basis) that are not deemed beneficially owned due to a Beneficial Ownership Limitation the reporting person elected at 9.99%.
Faeth Therapeutics, Inc. established an at-the-market stock offering program that allows it to sell common stock with an aggregate offering price of up to $150,000,000 through TD Securities (USA) LLC under a new Sales Agreement. The agent will earn a commission of up to 3.0% on shares sold.
The company also reported that on June 15, 2026, 24,435.594 shares of its Series B Non-Voting Convertible Preferred Stock automatically converted into 24,435,594 shares of common stock, resulting in 25,778,754 shares of common stock outstanding as of that date.
Faeth Therapeutics, Inc. filed a shelf registration and prospectus supplement to offer up to $150,000,000 of common stock under a sales agreement with TD Securities (USA) LLC (TD Cowen) as an at-the-market program. Shares may be sold from time to time on Nasdaq at market prices and the company will receive net proceeds from sales.
The prospectus describes the securities that may be offered under the base shelf (common stock, preferred stock, debt securities and warrants), notes that PIKTOR is in ongoing clinical trials with topline Phase 2 data anticipated by year-end 2026, and discloses corporate and charter details including an outstanding Series B Non-Voting Convertible Preferred Stock balance of 501.899 shares convertible at 1,000 common shares per preferred share.
Sensei Biotherapeutics, Inc. director Saira Ramasastry received a grant of stock options covering 25,000 shares of common stock. The options have an exercise price of $13.00 per share and expire on June 11, 2036.
The options vest in 36 equal monthly installments over three years, so they are fully vested by June 12, 2029, as long as she continues serving with the company. After this grant, she holds options for 25,000 shares directly.